Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05553873
Recruiting Observational

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

NCT05553873 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Milano Bicocca
Phase
Observational
Started
2022-09-08
Last updated
2024-01-02

Condition(s) studied

Myeloproliferative DiseaseInflammatory Markers

Study summary

This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years at the time of diagnosis of MPN Ph negative * Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000) * Obtaining informed consent Exclusion Criteria: * Life expectancy of less than 6 months * Accelerated phase myelofibrosis or MPN with signs of leukemic evolution

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Azienda Ospedaliera Universitaria Consorziale Policlinico Bari Italy Recruiting
Policlinico Sant'Orsola Malpighi Bologna Italy Recruiting
ASST Spedali Civili di Brescia Brescia Italy Recruiting
Policlinico Vittorio Emanuele Catania Italy Recruiting
Ospedale Universitario Federico II Naples Italy Recruiting
Policlinico Umberto I, Università La Sapienza Roma Italy Recruiting
Azienda Ospedaliera Universitaria Città della Salute e delle Scienza Torino Italy Recruiting
Ospedale San Luigi di Orbassano - Ospedale Mauriziano Torino Italy Recruiting
Azienda Ospedaliera Universitaria Friuli Centrale Udine Italy Recruiting
Azienda Ospedaliera Universitaria Integrata Verona Italy Recruiting
Ospedale Belcolle Viterbo Italy Recruiting

More University of Milano Bicocca trials in Italy

The Natural History of Hospitalized COVID-19 Patients Recruiting
Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage Recruiting
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 Recruiting
Non-invasive Vibratory Stimulation of the Knee Muscles for the Improvement of the Somatosensory Input and Motor Performance Recruiting
Intracranial PrEssure Time dOse (ImPETO) Recruiting

Other trials for the same condition

ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia Starting soon
Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study) Active, not recruiting
Unveiling the Germline Predisposition to Myeloproliferative Neoplasms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05553873 on ClinicalTrials.gov ↗ ← All trials in Italy